Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02013362 |
Recruitment Status :
Completed
First Posted : December 17, 2013
Last Update Posted : November 9, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Phase I portion:
To evaluate the safety and tolerability of pralatrexate with concurrent vitamin B12 and folic acid supplementation in Japanese patients with relapsed or refractory PTCL and to determine the recommended dosage. Also, to evaluate pharmacokinetics.
Phase II portion:
To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peripheral T-cell Lymphoma | Drug: Pralatrexate injection Dietary Supplement: Vitamin B12 Dietary Supplement: Folic Acid | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
Actual Study Start Date : | March 2014 |
Actual Primary Completion Date : | December 2015 |
Actual Study Completion Date : | September 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Pralatrexate injection
Dietary Supplement: Vitamin B12, Folic Acid
|
Drug: Pralatrexate injection Dietary Supplement: Vitamin B12 Dietary Supplement: Folic Acid |
- Objective response rate (ORR) per independent central review committee [ Time Frame: From screening period until first documented disease progression or treatment discontinuation from any cause, whichever came first. Duration is approximately 3 years. ]The ORR is defined as the proportion of patients with complete response (CR) and partial response (PR). Response will be determined according to International Workshop Criteria (IWC). Assessments will be done at week 7 (end of Cycle 1), subsequently every 14 weeks (end of odd-numbered cycle).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Japanese patients at least 20 years of age.
- Patients histologically diagnosed with peripheral T-cell lymphoma by pathological diagnosis of biopsied lesion.
- Relapsed or refractory patients with a treatment history of at least one regimen.
- Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm in maximum diameter on computed tomography performed.
- Patients expected to survive for at least 3 months.
- ECOG PS 0-2.
- Patients with adequate hemopoietic efficacy, liver and kidney function.
- Patients from whom written consent has been obtained prior to study initiation.
Exclusion Criteria:
- Patients who received a chemotherapy agent or a high dose of a systemic adrenocorticosteroid within 21 days prior to initial administration of the study drug.
- Patients who received radiation therapy, phototherapy, or electron beam therapy within 21 days prior to initial administration of the study drug.
- Patients who received another study drug within 28 days prior to initial administration of the study drug.
- Patients who received antibody therapy within 100 days prior to initial administration of the study drug.
- Patients with a history of allogeneic hematopoietic stem cell transplantation. Or patients with a history of autologous hematopoietic stem cell transplantation within 100 days prior to initial administration of the study drug.
- Patients with cerebral metastasis or central nervous system lesion or a past history.
- Patients with active multiple primary cancer. Or patients with a history of a malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.
- Patients with severe cardiovascular disease.
- Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological investigation. Or patients positive for either HBc antibody or HBs antibody, and showing DNA more than sensitivity in HBV-DNA assay.
- Patients positive for CMV antigen on immunological investigation.
- Patients with infectious disease requiring treatment consisting of intravenous administration of antibacterial agent, fungicide, or antiviral drug.
- Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have insufficient pulmonary function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02013362
Japan | |
National Hospital Organization Nagoya Medical Center | |
Nagoya, Aichi, Japan, 460-0001 | |
National Cancer Center Hospital | |
Chuo, Tokyo, Japan, 104-0045 | |
Okayama University Hospital | |
Okayama,, Japan, 700-8558 |
Principal Investigator: | Kensei Tobinai, MD,PhD | National Cancer Center Hospital |
Responsible Party: | Mundipharma K.K. |
ClinicalTrials.gov Identifier: | NCT02013362 |
Other Study ID Numbers: |
PDX-JP1 |
First Posted: | December 17, 2013 Key Record Dates |
Last Update Posted: | November 9, 2017 |
Last Verified: | November 2017 |
Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Lymphoma, Non-Hodgkin Folic Acid Vitamin B 12 Hydroxocobalamin Vitamins Micronutrients Physiological Effects of Drugs Hematinics Vitamin B Complex |